Compare KLTR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | CCCC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.4M | 240.3M |
| IPO Year | 2021 | 2020 |
| Metric | KLTR | CCCC |
|---|---|---|
| Price | $1.71 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.50 | ★ $7.25 |
| AVG Volume (30 Days) | 348.9K | ★ 2.0M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,921,000.00 | $30,108,000.00 |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $1.36 | $1.09 |
| 52 Week High | $2.82 | $4.26 |
| Indicator | KLTR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 35.76 |
| Support Level | $1.64 | $2.00 |
| Resistance Level | $1.72 | $2.13 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 63.46 | 12.65 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.